Cancer: This rapid-cycle descriptive analysis project aims to learn about the patterns of use of molecular biomarkers (tumor or germline) and associated targeted cancer therapies for patients with new-onset solid tumors (all single primary invasive solid tumors) cared for in a variety of community and academic care settings.
Diabetes: This rapid-cycle descriptive analysis project is focused on describing and validating PCORnet data on the use of several major classes of glucose-lowering medications for type 2 diabetes.
Opioid Surveillance: This rapid-cycle descriptive analysis project aims to demonstrate PCORnet’s capacity to create a more robust Opioid Surveillance Data Set and address current gaps in timely access to clinical data necessary for surveillance, prevention, and intervention.
Patient-Reported Outcomes Measurement (PROM): This rapid-cycle descriptive analysis project provides an opportunity for demonstrating the utility and value of collecting patient-reported outcomes measures (PROMs) during routine care in a standardized format for use in research analyses conducted within PCORnet.
PCSK9 Inhibitors: The purpose of this rapid-cycle descriptive analysis project is to learn about the trends and prevalence of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a class of medication therapies used to lower LDL cholesterol, or bad cholesterol, and treat hyperlipidemia.
Hepatitis C: This 12-month rapid-cycle retrospective observational research study conducted by investigators using PCORnet infrastructure aims to evaluate whether patients with hepatitis C virus (HCV) who are prescribed newer direct-acting antiviral (DAA) medications experience higher rates of adverse events than HCV patients who are untreated.
Posted: January 5, 2018; Updated: May 30, 2019